Hong Kong biopharmaceutical company: Aptorum Group Limited (APM) (2010)

Aptorum Group Limited (NASDAQ: APM) was established in 2010 and is headquartered in Hong Kong. It has offices in London, United Kingdom, New York, Singapore, and Ontario, Canada. It has 36 full-time employees. It is a pharmaceutical company specializing in therapeutic drugs. Discovery, development and commercialization to treat diseases with unmet medical needs, especially infectious diseases and cancer.

Aptorum Group Limited

Aptorum Group Limited (APM):

Zhilin Group (Nasdaq: APM) is a biopharmaceutical company committed to the development and commercialization of a series of new medical and diagnostic technologies to respond to unmet medical needs. Zhilin Group’s current drug development projects include indications for orphan diseases, infectious diseases and metabolic diseases, some of which are targeted to enter clinical trials in 2020. Zhilin Group also operates a female health products business, and its Dioscorea Opposita bioactive nutritional tablets are currently being commercialized.

Zhilin Group can discover new therapeutic assets through the establishment of a drug discovery platform, such as systematic screening of existing approved drug molecules, and a microbiome-based research platform to treat metabolic diseases. Zhilin Group also conducts treatment and diagnosis projects in the fields of neurology, gastroenterology, metabolic disorders, women’s health and other diseases. It also has surgical robots and natural supplements for women experiencing menopause and related symptoms.

Zhilin Group firmly believes that by promoting the pace of development of medical innovation, especially inventions that can meet the current unmet medical needs and can significantly improve clinical and surgical experience, are important elements to improve the quality of human life and patient care. With this belief, Mr. Xuan Junyuan founded Zhilin Group to give full play to local outstanding professionals and abundant medical resources to promote coverage of multiple indications and the potential to become the first-in-class in the market (First-in-Class) /Best-in-Class) Research and development of innovative medical and diagnostic technologies. Combining multiple types of new preclinical medical inventions and diverse human resources, Zhilin Group emphasizes science, cooperation and entrepreneurial spirit, and is determined to become a world-class participant in the biopharmaceutical industry.

Aptorum Group Limited (APM) product line:

Smart-Act series

Aptorum Group Limited P1

Acticule seriesAptorum Group Limited P2

Claves seriesAptorum Group Limited P3

Nativus seriesAptorum Group Limited P4

other seriesAptorum Group Limited P5

Notify of
Inline Feedbacks
View all Intels

Asset evaluation and clearing service company: Heritage Global Inc. (HGBL) (1983)

Professional staffing and IT solutions company: ASGN Incorporated (ASGN) (1985)